4//SEC Filing
McCann Corey 4
Accession 0001062993-22-004977
CIK 0001835567other
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 4:40 PM ET
Size
10.6 KB
Accession
0001062993-22-004977
Insider Transaction Report
Form 4
McCann Corey
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2022-02-16+210,080→ 210,080 totalExercise: $4.06Exp: 2032-02-16→ Common Stock (210,080 underlying) - Award
Restricted Stock Units
2022-02-16+266,667→ 266,667 total→ Common Stock (266,667 underlying)
Holdings
- 8,157,565
Class A Common Stock
- 1,685,913(indirect: By Trust)
Class A Common Stock
- 986,517(indirect: By Trust)
Class A Common Stock
Footnotes (7)
- [F1]Updated to correct error in prior Form 4 filing.
- [F2]The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, with respect to these shares, except to the extent of his pecuniary interest therein.
- [F3]Shares held in The Corey M. McCann Irrevocable Trust of 2021. The trustee of The Corey M. McCann Irrevocable Trust of 2021 is Mia E. Moll.
- [F4]Shares held in The McCann Family Trust. The trustee of The McCann Family Trust is Concord Trust Company.
- [F5]25% of the shares underlying the option shall vest on January 14, 2023 and an additional 2.0833 and 1/3% of the shares shall vest on the last day of each calendar month thereafter.
- [F6]Each restricted stock unit represents a contingent right to receive one share of PEAR common stock.
- [F7]The restricted stock units shall vest and settle as to 33% of the shares on January 14, 2023, 33% of the shares on January 14, 2024 and the final 34% on January 14, 2025.
Issuer
Pear Therapeutics, Inc.
CIK 0001835567
Entity typeother
Related Parties
1- filerCIK 0001881049
Filing Metadata
- Form type
- 4
- Filed
- Feb 17, 7:00 PM ET
- Accepted
- Feb 18, 4:40 PM ET
- Size
- 10.6 KB